Edition:
United Kingdom

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

47.71USD
18 May 2018
Change (% chg)

$-2.87 (-5.67%)
Prev Close
$50.58
Open
$50.20
Day's High
$50.75
Day's Low
$47.07
Volume
405,018
Avg. Vol
355,252
52-wk High
$168.91
52-wk Low
$44.76

Select another date:

Thu, May 3 2018

BRIEF-Tesaro Reports Q1 Loss Per Share Of $2.98

* Q1 EARNINGS PER SHARE VIEW $-2.69 -- THOMSON REUTERS I/B/E/S

BRIEF-Tesaro Announces Positive Top-Line Results From Quadra Trial Of Zejula

* TESARO ANNOUNCES POSITIVE TOP-LINE RESULTS FROM QUADRA TRIAL OF ZEJULA

BRIEF-Tesaro Summarizes TSR-042 Clinical Data Presented At AACR

* TESARO INC - EXPECT TO COMPLETE ENROLLMENT IN MSI-H ENDOMETRIAL COHORT OF GARNET TRIAL BY END OF YEAR Source text for Eikon: Further company coverage:

BRIEF-Tesaro And Medison Enter Into Exclusive Distribution Agreement To Commercialize Zejula In Israel

* TESARO AND MEDISON ENTER INTO EXCLUSIVE DISTRIBUTION AGREEMENT TO COMMERCIALIZE ZEJULA® IN ISRAEL

BRIEF-Tesaro Says TOPACIO Data Demonstrates Compelling Clinical Activity Of Zejula In Patients With Type Of Ovarian Cancer

* DATA FROM TOPACIO TRIAL REPORTED AT SGO DEMONSTRATES COMPELLING CLINICAL ACTIVITY OF ZEJULA IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER

BRIEF-Tesaro Inc Q4 Loss Per Share $3.35

* TESARO ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 OPERATING RESULTS

BRIEF-Tesaro collaborates with Roche to evaluate their combination treatment for bladder cancer

* TESARO ANNOUNCES COLLABORATION TO EVALUATE COMBINATION OF ZEJULA® (NIRAPARIB) AND ANTI-PD-L1 CANCER IMMUNOTHERAPY IN METASTATIC BLADDER CANCER

BRIEF-Tesaro Says Anaphylactic Shock, Other Hypersensitivity Reactions Reported For Varubi Injectable Emulsion

* TESARO ANNOUNCES UPDATES TO THE U.S. PRESCRIBING INFORMATION FOR VARUBI (ROLAPITANT) INJECTABLE EMULSION

BRIEF-Tesaro secures $500 million non-dilutive term loan financing

* Tesaro secures $500 million non-dilutive term loan financing

Select another date: